ID   ATM_HUMAN               Reviewed;        3056 AA.
AC   Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   22-JAN-2014, sequence version 4.
DT   12-OCT-2022, entry version 253.
DE   RecName: Full=Serine-protein kinase ATM;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217};
DE   AltName: Full=Ataxia telangiectasia mutated;
DE            Short=A-T mutated;
GN   Name=ATM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003.
RX   PubMed=8589678; DOI=10.1093/hmg/4.11.2025;
RA   Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S.,
RA   Shiloh Y., Rotman G.;
RT   "The complete sequence of the coding region of the ATM gene reveals
RT   similarity to cell cycle regulators in different species.";
RL   Hum. Mol. Genet. 4:2025-2032(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS
RP   CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287.
RX   PubMed=8665503;
RA   Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L.,
RA   Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G.,
RA   Croce C.M., Negrini M.;
RT   "The ATM gene and susceptibility to breast cancer: analysis of 38 breast
RT   tumors reveals no evidence for mutation.";
RL   Cancer Res. 56:2726-2732(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9199932; DOI=10.1101/gr.7.6.592;
RA   Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A.,
RA   Gilad S., Shiloh Y., Rosenthal A.;
RT   "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic
RT   DNA containing the entire ATM gene.";
RL   Genome Res. 7:592-605(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983.
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548
RP   DEL.
RX   PubMed=8789452; DOI=10.1093/hmg/5.1.145;
RA   Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T.,
RA   McGuire G.M., Thick J.A., Taylor A.M.R.;
RT   "Mutations revealed by sequencing the 5' half of the gene for ataxia
RT   telangiectasia.";
RL   Hum. Mol. Genet. 5:145-149(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=9108147; DOI=10.1093/nar/25.9.1678;
RA   Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A.,
RA   Elroy-Stein O., Shiloh Y., Rotman G.;
RT   "Ataxia-telangiectasia: structural diversity of untranslated sequences
RT   suggests complex post-transcriptional regulation of ATM gene expression.";
RL   Nucleic Acids Res. 25:1678-1684(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428
RP   DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003.
RC   TISSUE=Fibroblast;
RX   PubMed=7792600; DOI=10.1126/science.7792600;
RA   Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L.,
RA   Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I.,
RA   Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A.,
RA   Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R.,
RA   Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.;
RT   "A single ataxia telangiectasia gene with a product similar to PI-3
RT   kinase.";
RL   Science 268:1749-1753(1995).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056.
RX   PubMed=8521392;
RA   Rasio D., Negrini M., Croce C.M.;
RT   "Genomic organization of the ATM locus involved in ataxia-telangiectasia.";
RL   Cancer Res. 55:6053-6057(1995).
RN   [12]
RP   PHOSPHORYLATION.
RX   PubMed=8969240; DOI=10.1074/jbc.271.52.33693;
RA   Chen G., Lee E.Y.-H.P.;
RT   "The product of the ATM gene is a 370-kDa nuclear phosphoprotein.";
RL   J. Biol. Chem. 271:33693-33697(1996).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9050866; DOI=10.1073/pnas.94.5.1840;
RA   Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y.,
RA   Tagle D.A.;
RT   "The ataxia-telangiectasia gene product, a constitutively expressed nuclear
RT   protein that is not up-regulated following genome damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997).
RN   [14]
RP   SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824.
RX   PubMed=9150358; DOI=10.1038/sj.onc.1201037;
RA   Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P.,
RA   Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A.,
RA   Ramsay J., Gatti R.A., Lavin M.F.;
RT   "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and
RT   discrimination between mutated and normal forms.";
RL   Oncogene 14:1911-1921(1997).
RN   [15]
RP   CATALYTIC ACTIVITY.
RX   PubMed=8988033;
RA   Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.;
RT   "ATM gene product phosphorylates I kappa B-alpha.";
RL   Cancer Res. 57:24-27(1997).
RN   [16]
RP   INTERACTION WITH ABL1.
RX   PubMed=9168117; DOI=10.1038/387520a0;
RA   Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K.,
RA   Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S.,
RA   Kufe D., Lavin M.F.;
RT   "Interaction between ATM protein and c-Abl in response to DNA damage.";
RL   Nature 387:520-523(1997).
RN   [17]
RP   ACTIVITY REGULATION.
RX   PubMed=9766667;
RA   Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E.,
RA   Abraham R.T.;
RT   "Inhibition of phosphoinositide 3-kinase related kinases by the
RT   radiosensitizing agent wortmannin.";
RL   Cancer Res. 58:4375-4382(1998).
RN   [18]
RP   FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY.
RX   PubMed=9843217; DOI=10.1038/3882;
RA   Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K.,
RA   Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.;
RT   "ATM associates with and phosphorylates p53: mapping the region of
RT   interaction.";
RL   Nat. Genet. 20:398-400(1998).
RN   [19]
RP   INTERACTION WITH BETA-ADAPTIN.
RX   PubMed=9707615; DOI=10.1073/pnas.95.17.10146;
RA   Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S.,
RA   Darnell R.B., Shiloh Y., Kastan M.B.;
RT   "ATM binds to beta-adaptin in cytoplasmic vesicles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF TP53.
RX   PubMed=9733514; DOI=10.1126/science.281.5383.1674;
RA   Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L.,
RA   Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.;
RT   "Enhanced phosphorylation of p53 by ATM in response to DNA damage.";
RL   Science 281:1674-1677(1998).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND
RP   ASN-2875.
RX   PubMed=9733515; DOI=10.1126/science.281.5383.1677;
RA   Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K.,
RA   Appella E., Kastan M.B., Siliciano J.D.;
RT   "Activation of the ATM kinase by ionizing radiation and phosphorylation of
RT   p53.";
RL   Science 281:1677-1679(1998).
RN   [22]
RP   DNA-BINDING.
RX   PubMed=10500142; DOI=10.1073/pnas.96.20.11134;
RA   Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J.,
RA   Jackson S.P.;
RT   "Purification and DNA binding properties of the ataxia-telangiectasia gene
RT   product ATM.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF BRCA1.
RX   PubMed=10550055; DOI=10.1126/science.286.5442.1162;
RA   Cortez D., Wang Y., Qin J., Elledge S.J.;
RT   "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage
RT   response to double-strand breaks.";
RL   Science 286:1162-1166(1999).
RN   [24]
RP   IDENTIFICATION OF ATM AS MEMBER OF BASC.
RX   PubMed=10783165;
RA   Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.;
RT   "BASC, a super complex of BRCA1-associated proteins involved in the
RT   recognition and repair of aberrant DNA structures.";
RL   Genes Dev. 14:927-939(2000).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF NBN.
RX   PubMed=10766245; DOI=10.1038/35007091;
RA   Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J.,
RA   Kastan M.B.;
RT   "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.";
RL   Nature 404:613-617(2000).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF NBN.
RX   PubMed=10839545; DOI=10.1038/35013089;
RA   Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N.,
RA   O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G.,
RA   Livingston D.M., Weaver D.T.;
RT   "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a
RT   DNA damage response.";
RL   Nature 405:477-482(2000).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF CTIP.
RX   PubMed=10910365; DOI=10.1038/35018134;
RA   Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P.,
RA   Lee W.-H.;
RT   "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA
RT   damage response.";
RL   Nature 406:210-215(2000).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF NBN.
RX   PubMed=10802669; DOI=10.1038/75508;
RA   Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S.,
RA   Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.;
RT   "ATM-dependent phosphorylation of nibrin in response to radiation
RT   exposure.";
RL   Nat. Genet. 25:115-119(2000).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF CHEK2.
RX   PubMed=10973490; DOI=10.1073/pnas.190030497;
RA   Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.;
RT   "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF TERF1.
RX   PubMed=11375976; DOI=10.1074/jbc.m011534200;
RA   Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.;
RT   "Telomeric protein Pin2/TRF1 as an important ATM target in response to
RT   double strand DNA breaks.";
RL   J. Biol. Chem. 276:29282-29291(2001).
RN   [31]
RP   INTERACTION WITH RAD17.
RX   PubMed=11418864; DOI=10.1038/35082110;
RA   Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A.,
RA   Chen S.M., Abraham R.T., Wang X.-F.;
RT   "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic
RT   stress responses.";
RL   Nature 411:969-974(2001).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF FANCD2.
RX   PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x;
RA   Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C.,
RA   Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.;
RT   "Convergence of the Fanconi anemia and ataxia telangiectasia signaling
RT   pathways.";
RL   Cell 109:459-472(2002).
RN   [33]
RP   PHOSPHORYLATION BY NUAK1.
RX   PubMed=12409306; DOI=10.1074/jbc.m206025200;
RA   Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.;
RT   "Identification of a novel protein kinase mediating Akt survival signaling
RT   to the ATM protein.";
RL   J. Biol. Chem. 278:48-53(2003).
RN   [34]
RP   PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF
RP   SER-1981.
RX   PubMed=12556884; DOI=10.1038/nature01368;
RA   Bakkenist C.J., Kastan M.B.;
RT   "DNA damage activates ATM through intermolecular autophosphorylation and
RT   dimer dissociation.";
RL   Nature 421:499-506(2003).
RN   [35]
RP   FUNCTION IN DNA DAMAGE RESPONSE, AND INTERACTION WITH PPP5C.
RX   PubMed=14871926; DOI=10.1101/gad.1176004;
RA   Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T.,
RA   Wang X.F.;
RT   "Requirement of protein phosphatase 5 in DNA-damage-induced ATM
RT   activation.";
RL   Genes Dev. 18:249-254(2004).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF DCLRE1C, AND INTERACTION WITH DCLRE1C.
RX   PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in the
RT   G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [37]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15448695; DOI=10.1038/ncb1170;
RA   Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P.,
RA   Jansson M., La Thangue N.B.;
RT   "A new effector pathway links ATM kinase with the DNA damage response.";
RL   Nat. Cell Biol. 6:968-976(2004).
RN   [38]
RP   INTERACTION WITH EEF1E1.
RX   PubMed=15680327; DOI=10.1016/j.cell.2004.11.054;
RA   Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H.,
RA   Choi Y.H., Choi D., Lee K.S., Kim S.;
RT   "The haploinsufficient tumor suppressor p18 upregulates p53 via
RT   interactions with ATM/ATR.";
RL   Cell 120:209-221(2005).
RN   [39]
RP   FUNCTION.
RX   PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015;
RA   Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.;
RT   "ATM-dependent phosphorylation of ATF2 is required for the DNA damage
RT   response.";
RL   Mol. Cell 18:577-587(2005).
RN   [40]
RP   INTERACTION WITH KAT8.
RX   PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005;
RA   Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T.,
RA   Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.;
RT   "Involvement of human MOF in ATM function.";
RL   Mol. Cell. Biol. 25:5292-5305(2005).
RN   [41]
RP   FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY.
RX   PubMed=16086026; DOI=10.1038/nsmb972;
RA   Kaygun H., Marzluff W.F.;
RT   "Regulated degradation of replication-dependent histone mRNAs requires both
RT   ATR and Upf1.";
RL   Nat. Struct. Mol. Biol. 12:794-800(2005).
RN   [42]
RP   INTERACTION WITH HTATIP, PHOSPHORYLATION AT SER-1981, AND ACETYLATION.
RX   PubMed=16141325; DOI=10.1073/pnas.0504211102;
RA   Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.;
RT   "A role for the Tip60 histone acetyltransferase in the acetylation and
RT   activation of ATM.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005).
RN   [43]
RP   PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC
RP   ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=16858402; DOI=10.1038/sj.emboj.7601231;
RA   Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.;
RT   "Involvement of novel autophosphorylation sites in ATM activation.";
RL   EMBO J. 25:3504-3514(2006).
RN   [44]
RP   INTERACTION WITH ATMIN.
RX   PubMed=17525732; DOI=10.1038/sj.emboj.7601733;
RA   Kanu N., Behrens A.;
RT   "ATMIN defines an NBS1-independent pathway of ATM signalling.";
RL   EMBO J. 26:2933-2941(2007).
RN   [45]
RP   ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND
RP   LYS-3018.
RX   PubMed=17923702; DOI=10.1128/mcb.01382-07;
RA   Sun Y., Xu Y., Roy K., Price B.D.;
RT   "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase
RT   activity.";
RL   Mol. Cell. Biol. 27:8502-8509(2007).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [47]
RP   INTERACTION WITH CEP164.
RX   PubMed=18283122; DOI=10.1101/gad.1627708;
RA   Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.;
RT   "Cep164 is a mediator protein required for the maintenance of genomic
RT   stability through modulation of MDC1, RPA, and CHK1.";
RL   Genes Dev. 22:587-600(2008).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [49]
RP   INTERACTION WITH NABP2.
RX   PubMed=18449195; DOI=10.1038/nature06883;
RA   Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K.,
RA   Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K.,
RA   Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K.,
RA   White M.F., Khanna K.K.;
RT   "Single-stranded DNA-binding protein hSSB1 is critical for genomic
RT   stability.";
RL   Nature 453:677-681(2008).
RN   [50]
RP   INTERACTION WITH DDX1.
RX   PubMed=18710941; DOI=10.1128/mcb.01053-08;
RA   Li L., Monckton E.A., Godbout R.;
RT   "A role for DEAD box 1 at DNA double-strand breaks.";
RL   Mol. Cell. Biol. 28:6413-6425(2008).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [52]
RP   FUNCTION AS DYRK2 KINASE.
RX   PubMed=19965871; DOI=10.1074/jbc.m109.042341;
RA   Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.;
RT   "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 285:4909-4919(2010).
RN   [53]
RP   INTERACTION WITH TTI1.
RX   PubMed=20810650; DOI=10.1101/gad.1934210;
RA   Hurov K.E., Cotta-Ramusino C., Elledge S.J.;
RT   "A genetic screen identifies the Triple T complex required for DNA damage
RT   signaling and ATM and ATR stability.";
RL   Genes Dev. 24:1939-1950(2010).
RN   [54]
RP   INTERACTION WITH TELO2.
RX   PubMed=20801936; DOI=10.1101/gad.1956410;
RA   Takai H., Xie Y., de Lange T., Pavletich N.P.;
RT   "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and
RT   ATR complexes.";
RL   Genes Dev. 24:2019-2030(2010).
RN   [55]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.m110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [56]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [57]
RP   PHOSPHORYLATION AT SER-1981.
RX   PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005;
RA   Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y.,
RA   You H.J.;
RT   "Protein phosphatase 5 is necessary for ATR-mediated DNA repair.";
RL   Biochem. Biophys. Res. Commun. 404:476-481(2011).
RN   [58]
RP   INTERACTION WITH BRAT1.
RX   PubMed=22977523; DOI=10.3892/etm.2011.232;
RA   So E.Y., Ouchi T.;
RT   "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK
RT   catalytic subunit.";
RL   Exp. Ther. Med. 2:443-447(2011).
RN   [59]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [60]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [61]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [62]
RP   FUNCTION IN PHOSPHORYLATION OF FBXW7.
RX   PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010;
RA   Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.;
RT   "FBXW7 facilitates nonhomologous end-joining via K63-linked
RT   polyubiquitylation of XRCC4.";
RL   Mol. Cell 61:419-433(2016).
RN   [63]
RP   FUNCTION.
RX   PubMed=29203878; DOI=10.1038/s41467-017-02114-x;
RA   Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D.,
RA   Zhu X.D.;
RT   "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair
RT   pathway choice.";
RL   Nat. Commun. 8:1921-1921(2017).
RN   [64]
RP   FUNCTION.
RX   PubMed=30612738; DOI=10.1016/j.cell.2018.11.024;
RA   Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J.,
RA   Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L.,
RA   Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T.,
RA   Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M.,
RA   Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T.,
RA   Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.;
RT   "UBQLN4 represses homologous recombination and is overexpressed in
RT   aggressive tumors.";
RL   Cell 0:0-0(2019).
RN   [65]
RP   FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY.
RX   PubMed=30886146; DOI=10.1038/s41467-019-09175-0;
RA   Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.;
RT   "UFL1 promotes histone H4 ufmylation and ATM activation.";
RL   Nat. Commun. 10:1242-1242(2019).
RN   [66]
RP   ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF
RP   LYS-3016.
RX   PubMed=30944854; DOI=10.1126/sciadv.aav1118;
RA   Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L.,
RA   Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.;
RT   "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA
RT   damage repair.";
RL   Sci. Adv. 5:EAAV1118-EAAV1118(2019).
RN   [67] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1}
RP   STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND
RP   SUBUNIT.
RX   PubMed=28508083; DOI=10.1126/sciadv.1700933;
RA   Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B.,
RA   Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.;
RT   "Structures of closed and open conformations of dimeric human ATM.";
RL   Sci. Adv. 3:E1700933-E1700933(2017).
RN   [68]
RP   VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827.
RX   PubMed=8755918;
RA   McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y.,
RA   Lennox G.G., Taylor A.M.R.;
RT   "Mutations associated with variant phenotypes in ataxia-telangiectasia.";
RL   Am. J. Hum. Genet. 59:320-330(1996).
RN   [69]
RP   VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438.
RX   PubMed=8808599;
RA   Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D.,
RA   Concannon P.;
RT   "A high frequency of distinct ATM gene mutations in ataxia-
RT   telangiectasia.";
RL   Am. J. Hum. Genet. 59:839-846(1996).
RN   [70]
RP   VARIANTS 705-PHE--PRO-707 AND 2546-SER--ILE-2548 DEL, AND VARIANTS CYS-49;
RP   LEU-858; ARG-1054; PHE-1420 AND ARG-1691.
RX   PubMed=8797579;
RA   Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B.,
RA   Croce C.M., Hammarstroem L.;
RT   "ATM mutations in cancer families.";
RL   Cancer Res. 56:4130-4133(1996).
RN   [71]
RP   VARIANT AT 705-PHE--PRO-707, AND VARIANTS LEU-858 AND ARG-1054.
RX   PubMed=9043869; DOI=10.1159/000472231;
RA   Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M.,
RA   James M.R., Negrini M., Webster A.D.B., Hammarstroem L.;
RT   "Exon-scanning mutation analysis of the ATM gene in patients with ataxia-
RT   telangiectasia.";
RL   Eur. J. Hum. Genet. 4:352-355(1996).
RN   [72]
RP   VARIANT AT ARG-2867.
RX   PubMed=8698354; DOI=10.1007/s004390050202;
RA   Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.;
RT   "New mutations in the ataxia telangiectasia gene.";
RL   Hum. Genet. 98:246-249(1996).
RN   [73]
RP   VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND
RP   GLY-2904.
RX   PubMed=8845835; DOI=10.1093/hmg/5.4.433;
RA   Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G.,
RA   Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O.,
RA   Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F.,
RA   Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.;
RT   "Predominance of null mutations in ataxia-telangiectasia.";
RL   Hum. Mol. Genet. 5:433-439(1996).
RN   [74]
RP   POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407;
RP   SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442;
RP   2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810
RP   DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890.
RX   PubMed=9288106; DOI=10.1038/ng0997-96;
RA   Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C.,
RA   Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.;
RT   "Clustering of missense mutations in the ataxia-telangiectasia gene in a
RT   sporadic T-cell leukaemia.";
RL   Nat. Genet. 17:96-99(1997).
RN   [75]
RP   POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008.
RX   PubMed=9334731; DOI=10.1038/nm1097-1155;
RA   Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S.,
RA   Bar-Shira A., James M.R., Lichter P., Doehner H.;
RT   "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.";
RL   Nat. Med. 3:1155-1159(1997).
RN   [76]
RP   VARIANT AT CYS-2832.
RX   PubMed=9443866; DOI=10.1086/301673;
RA   Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S.,
RA   Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E.,
RA   Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.;
RT   "Ataxia-telangiectasia: identification and detection of founder-effect
RT   mutations in the ATM gene in ethnic populations.";
RL   Am. J. Hum. Genet. 62:86-97(1998).
RN   [77]
RP   POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001;
RP   ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548
RP   DEL; ASP-2554; GLY-2668 AND CYS-2827.
RX   PubMed=9463314; DOI=10.1086/301706;
RA   Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P.,
RA   Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N.,
RA   Byrd P.J., Taylor A.M.R.;
RT   "ATM mutations and phenotypes in ataxia-telangiectasia families in the
RT   British Isles: expression of mutant ATM and the risk of leukemia, lymphoma,
RT   and breast cancer.";
RL   Am. J. Hum. Genet. 62:334-345(1998).
RN   [78]
RP   VARIANT AT 1812-ALA-PHE-1813 DELINS VAL.
RX   PubMed=9497252; DOI=10.1086/301755;
RA   Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M.,
RA   Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.;
RT   "Genotype-phenotype relationships in ataxia-telangiectasia and variants.";
RL   Am. J. Hum. Genet. 62:551-561(1998).
RN   [79]
RP   VARIANT AT PRO-2656.
RX   PubMed=9450874;
RX   DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.0.co;2-w;
RA   Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E.,
RA   Ohno K., Hori N., Sato K., Takeshita K.;
RT   "Ataxia-telangiectasia without immunodeficiency: novel point mutations
RT   within and adjacent to the phosphatidylinositol 3-kinase-like domain.";
RL   Am. J. Med. Genet. 75:141-144(1998).
RN   [80]
RP   VARIANT TPLL GLY-2486.
RX   PubMed=9573030;
RA   Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F.,
RA   Stern M.-H.;
RT   "Inactivation of the ATM gene in T-cell prolymphocytic leukemias.";
RL   Blood 91:3920-3926(1998).
RN   [81]
RP   VARIANTS 2855-ARG-ILE-2856 AND CYS-3008, AND VARIANT VAL-1853.
RX   PubMed=9872980; DOI=10.1101/gr.8.12.1245;
RA   Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C.,
RA   Fodor S.P.A., Tagle D.A., Collins F.S.;
RT   "Strategies for mutational analysis of the large multiexon ATM gene using
RT   high-density oligonucleotide arrays.";
RL   Genome Res. 8:1245-1258(1998).
RN   [82]
RP   VARIANT AT 2625-GLU-PRO-2626.
RX   PubMed=9521587; DOI=10.1007/s004390050675;
RA   van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M.,
RA   van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.;
RT   "A double missense mutation in the ATM gene of a Dutch family with ataxia
RT   telangiectasia.";
RL   Hum. Genet. 102:187-191(1998).
RN   [83]
RP   VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853.
RX   PubMed=9711876;
RX   DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f;
RA   Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M.,
RA   Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O.,
RA   Hayashi K.;
RT   "ATM mutations in patients with ataxia telangiectasia screened by a
RT   hierarchical strategy.";
RL   Hum. Mutat. 12:186-195(1998).
RN   [84]
RP   VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566.
RX   PubMed=9792409;
RX   DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h;
RA   Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J.,
RA   Jaspers N.G.J., van 't Veer L.J.;
RT   "ATM germline mutations in classical ataxia-telangiectasia patients in the
RT   Dutch population.";
RL   Hum. Mutat. 12:330-337(1998).
RN   [85]
RP   VARIANTS AT ARG-2491 AND GLY-2909.
RX   PubMed=9792410;
RX   DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9;
RA   Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T.,
RA   Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J.,
RA   Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.;
RT   "Ataxia-telangiectasia in the Japanese population: identification of
RT   R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being
RT   relatively common mutations.";
RL   Hum. Mutat. 12:338-343(1998).
RN   [86]
RP   VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008.
RX   PubMed=9488043; DOI=10.1038/sj.onc.1201603;
RA   Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E.,
RA   Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.;
RT   "ATM is usually rearranged in T-cell prolymphocytic leukaemia.";
RL   Oncogene 16:789-796(1998).
RN   [87]
RP   ERRATUM OF PUBMED:9488043.
RA   Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E.,
RA   Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.;
RL   Oncogene 16:2955-2955(1998).
RN   [88]
RP   POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853;
RP   ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018.
RX   PubMed=10397742;
RA   Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.;
RT   "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic
RT   lymphocytic leukemia.";
RL   Blood 94:748-753(1999).
RN   [89]
RP   POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424.
RX   PubMed=9892178;
RA   Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M.,
RA   Albitar M., Reed J.C., Croce C.M.;
RT   "ATM mutations in B-cell chronic lymphocytic leukemia.";
RL   Cancer Res. 59:24-27(1999).
RN   [90]
RP   VARIANT AT PRO-1465.
RX   PubMed=10234507; DOI=10.1038/sj.ejhg.5200288;
RA   Izatt L., Vessey C., Hodgson S.V., Solomon E.;
RT   "Rapid and efficient ATM mutation detection by fluorescent chemical
RT   cleavage of mismatch: identification of four novel mutations.";
RL   Eur. J. Hum. Genet. 7:310-320(1999).
RN   [91]
RP   VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853
RP   AND SER-2765.
RX   PubMed=10534763;
RX   DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.0.co;2-x;
RA   Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G.,
RA   Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.;
RT   "Identification of germline missense mutations and rare allelic variants in
RT   the ATM gene in early-onset breast cancer.";
RL   Genes Chromosomes Cancer 26:286-294(1999).
RN   [92]
RP   VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227;
RP   ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49;
RP   LEU-858; ARG-1054; ASN-1853 AND VAL-1853.
RX   PubMed=9887333; DOI=10.1093/hmg/8.1.69;
RA   Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B.,
RA   Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A.,
RA   Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.;
RT   "Characterization of ATM gene mutations in 66 ataxia telangiectasia
RT   families.";
RL   Hum. Mol. Genet. 8:69-79(1999).
RN   [93]
RP   VARIANTS AT CYS-49; 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL;
RP   1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER;
RP   2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056
RP   DEL AND ARG-2855.
RX   PubMed=10425038;
RX   DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e;
RA   Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J.,
RA   Wang Z., Yang Z., Cheng R., Gatti R.A.;
RT   "New mutations, polymorphisms, and rare variants in the ATM gene detected
RT   by a novel SSCP strategy.";
RL   Hum. Mutat. 14:156-162(1999).
RN   [94]
RP   POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054;
RP   THR-2274 AND ALA-2695.
RX   PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4;
RA   Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J.,
RA   Moss P.A.H., Taylor A.M.R.;
RT   "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic
RT   lymphocytic leukaemia.";
RL   Lancet 353:26-29(1999).
RN   [95]
RP   VARIANT ARG-1054.
RX   PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0;
RA   Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.;
RT   "Missense mutations at ATM gene and cancer risk.";
RL   Lancet 353:1276-1276(1999).
RN   [96]
RP   ERRATUM OF PUBMED:10217116.
RA   Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.;
RL   Lancet 354:780-780(1999).
RN   [97]
RP   VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL;
RP   GLN-2625; CYS-2832; 2855-ARG-ILE-2856 AND CYS-3008, AND VARIANTS VAL-1853
RP   AND ILE-2438.
RX   PubMed=10817650;
RX   DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#;
RA   Li A., Swift M.;
RT   "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-
RT   T patients.";
RL   Am. J. Med. Genet. 92:170-177(2000).
RN   [98]
RP   VARIANTS AT 35-ARG--VAL-3056 DEL; CYS-49; 292-LEU; 393-TRP--VAL-3056 DEL;
RP   LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063;
RP   CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-AER--SER-2549 DEL; GLU-2625
RP   AND PRO-2626.
RX   PubMed=10873394; DOI=10.1006/mgme.2000.2998;
RA   Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O.,
RA   Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.;
RT   "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein
RT   expression, mutations, and radiosensitivity.";
RL   Mol. Genet. Metab. 70:122-133(2000).
RN   [99]
RP   VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008.
RX   PubMed=10706620; DOI=10.1073/pnas.050400997;
RA   Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.;
RT   "Mantle cell lymphoma is characterized by inactivation of the ATM gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000).
RN   [100]
RP   VARIANTS TRP-45 AND CYS-49.
RX   PubMed=11897822; DOI=10.1136/jmg.39.3.192;
RA   Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H.,
RA   Boerresen-Dale A.L., Winqvist R.;
RT   "ATM mutations in Finnish breast cancer patients.";
RL   J. Med. Genet. 39:192-196(2002).
RN   [101]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250;
RP   PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546;
RP   LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054;
RP   PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475;
RP   SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961;
RP   ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443;
RP   ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [102]
RP   VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396
RP   AND HIS-2719.
RX   PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x;
RA   Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S.,
RA   Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.;
RT   "ATM germline mutations in Spanish early-onset breast cancer patients
RT   negative for BRCA1/BRCA2 mutations.";
RL   Clin. Genet. 73:465-473(2008).
RN   [103]
RP   FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743;
RP   THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL;
RP   ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND
RP   CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322;
RP   ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF
RP   LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452;
RP   SER-2685; PRO-2699; ASP-2708 AND GLN-2730.
RX   PubMed=19431188; DOI=10.1002/humu.21034;
RA   Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.;
RT   "Modeling ATM mutant proteins from missense changes confirms retained
RT   kinase activity.";
RL   Hum. Mutat. 30:1222-1230(2009).
RN   [104]
RP   VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND
RP   VAL-1853.
RX   PubMed=28202063; DOI=10.1186/s12920-017-0244-7;
RA   Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H.,
RA   Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.;
RT   "Next-generation sequencing in familial breast cancer patients from
RT   Lebanon.";
RL   BMC Med. Genomics 10:8-8(2017).
RN   [105]
RP   VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627;
RP   LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046;
RP   ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND
RP   PHOSPHORYLATION.
RX   PubMed=27664052; DOI=10.1007/s12017-016-8440-8;
RA   Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J.,
RA   Santamaria M., Santos J.L., Molina I.J.;
RT   "Molecular and functional characterization of a cohort of Spanish patients
RT   with ataxia-telangiectasia.";
RL   NeuroMolecular Med. 19:161-174(2017).
RN   [106]
RP   VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869;
RP   ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464;
RP   PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056.
RX   PubMed=28726808; DOI=10.1038/gim.2017.85;
RA   Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A.,
RA   Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.;
RT   "Prevalence of germ-line mutations in cancer genes among pancreatic cancer
RT   patients with a positive family history.";
RL   Genet. Med. 20:119-127(2018).
CC   -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint
CC       signaling upon double strand breaks (DSBs), apoptosis and genotoxic
CC       stresses such as ionizing ultraviolet A light (UVA), thereby acting as
CC       a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-
CC       Q. Phosphorylates 'Ser-139' of histone variant H2AX at double strand
CC       breaks (DSBs), thereby regulating DNA damage response mechanism. Also
CC       plays a role in pre-B cell allelic exclusion, a process leading to
CC       expression of a single immunoglobulin heavy chain allele to enforce
CC       clonality and monospecific recognition by the B-cell antigen receptor
CC       (BCR) expressed on individual B-lymphocytes. After the introduction of
CC       DNA breaks by the RAG complex on one immunoglobulin allele, acts by
CC       mediating a repositioning of the second allele to pericentromeric
CC       heterochromatin, preventing accessibility to the RAG complex and
CC       recombination of the second allele. Also involved in signal
CC       transduction and cell cycle control. May function as a tumor
CC       suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates
CC       DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, NFKBIA, BRCA1, CTIP, nibrin
CC       (NBN), TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C (PubMed:9843217,
CC       PubMed:9733515, PubMed:10550055, PubMed:10766245, PubMed:10839545,
CC       PubMed:10910365, PubMed:10802669, PubMed:10973490, PubMed:11375976,
CC       PubMed:12086603, PubMed:15456891, PubMed:19965871, PubMed:30612738,
CC       PubMed:30886146, PubMed:26774286). May play a role in vesicle and/or
CC       protein transport. Could play a role in T-cell development, gonad and
CC       neurological function. Plays a role in replication-dependent histone
CC       mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus
CC       in response to genotoxic stress prevents its MDM2-mediated
CC       ubiquitination and subsequent proteasome degradation. Phosphorylates
CC       ATF2 which stimulates its function in DNA damage response.
CC       Phosphorylates ERCC6 which is essential for its chromatin remodeling
CC       activity at DNA double-strand breaks (PubMed:29203878). Phosphorylates
CC       TTC5/STRAP at 'Ser-203' in the cytoplasm in response to DNA damage,
CC       which promotes TTC5/STRAP nuclear localization (PubMed:15448695).
CC       {ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245,
CC       ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545,
CC       ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490,
CC       ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603,
CC       ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926,
CC       ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026,
CC       ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702,
CC       ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871,
CC       ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878,
CC       ECO:0000269|PubMed:30612738, ECO:0000269|PubMed:30886146,
CC       ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515,
CC       ECO:0000269|PubMed:9843217}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:16858402,
CC         ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146,
CC         ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000305|PubMed:15448695};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:28508083,
CC         ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217};
CC   -!- ACTIVITY REGULATION: Inhibited by wortmannin.
CC       {ECO:0000269|PubMed:9766667}.
CC   -!- SUBUNIT: Homodimer (PubMed:28508083). Dimers or tetramers in inactive
CC       state. On DNA damage, autophosphorylation dissociates ATM into monomers
CC       rendering them catalytically active. Binds p53/TP53, ABL1, BRCA1,
CC       NBN/nibrin and TERF1. Part of the BRCA1-associated genome surveillance
CC       complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2
CC       and the RAD50-MRE11-NBN protein complex. This association could be a
CC       dynamic process changing throughout the cell cycle and within
CC       subnuclear domains. Interacts with RAD17; DNA damage promotes the
CC       association. Interacts with EEF1E1; the interaction, induced on DNA
CC       damage, up-regulates TP53. Interacts with DCLRE1C, KAT8, KAT5, NABP2,
CC       ATMIN and CEP164. Interacts with AP2B1 and AP3B2; the interaction
CC       occurs in cytoplasmic vesicles (By similarity). Interacts with TELO2
CC       and TTI1. Interacts with DDX1. Interacts with BRAT1. Interacts with
CC       CYREN (via XLF motif) (By similarity). {ECO:0000250|UniProtKB:Q62388,
CC       ECO:0000269|PubMed:11418864, ECO:0000269|PubMed:12556884,
CC       ECO:0000269|PubMed:14871926, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15680327, ECO:0000269|PubMed:15923642,
CC       ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:17525732,
CC       ECO:0000269|PubMed:18283122, ECO:0000269|PubMed:18449195,
CC       ECO:0000269|PubMed:18710941, ECO:0000269|PubMed:20427287,
CC       ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650,
CC       ECO:0000269|PubMed:22977523, ECO:0000269|PubMed:28508083,
CC       ECO:0000269|PubMed:9168117, ECO:0000269|PubMed:9707615,
CC       ECO:0000269|PubMed:9843217}.
CC   -!- INTERACTION:
CC       Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428;
CC       Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543;
CC       Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202;
CC       Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195;
CC       Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340;
CC       Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477;
CC       Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279;
CC       Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542;
CC       Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644;
CC       Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336;
CC       Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228;
CC       Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844;
CC       Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374;
CC       Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132;
CC       Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083;
CC       Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674;
CC       Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997;
CC       Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018;
CC       Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637;
CC       Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540;
CC       Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680;
CC       Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866,
CC       ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000250|UniProtKB:Q62388}. Note=Primarily nuclear. Found also in
CC       endocytic vesicles in association with beta-adaptin.
CC       {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}.
CC   -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver,
CC       lung, placenta, brain, heart, spleen, thymus, testis, ovary, small
CC       intestine, colon and leukocytes.
CC   -!- INDUCTION: By ionizing radiation.
CC   -!- DOMAIN: The FATC domain is required for interaction with KAT5.
CC       {ECO:0000269|PubMed:16141325}.
CC   -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306).
CC       Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA
CC       damage-mediated activation of the kinase (PubMed:12556884,
CC       PubMed:16141325, PubMed:16858402, PubMed:21144835, PubMed:27664052).
CC       During the late stages of DNA damage response, dephosphorylated
CC       following deacetylation by SIRT7, leading to ATM deactivation
CC       (PubMed:30944854). {ECO:0000269|PubMed:12409306,
CC       ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325,
CC       ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835,
CC       ECO:0000269|PubMed:27664052, ECO:0000269|PubMed:30944854}.
CC   -!- PTM: Acetylation, on DNA damage, is required for activation of the
CC       kinase activity, dimer-monomer transition, and subsequent
CC       autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325,
CC       PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro
CC       by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late
CC       stages of DNA damage response, promoting ATM dephosphorylation and
CC       subsequent deactivation (PubMed:30944854).
CC       {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325,
CC       ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702,
CC       ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}.
CC   -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive
CC       disorder characterized by progressive cerebellar ataxia, dilation of
CC       the blood vessels in the conjunctiva and eyeballs, immunodeficiency,
CC       growth retardation and sexual immaturity. Patients have a strong
CC       predisposition to cancer; about 30% of patients develop tumors,
CC       particularly lymphomas and leukemias. Cells from affected individuals
CC       are highly sensitive to damage by ionizing radiation and resistant to
CC       inhibition of DNA synthesis following irradiation.
CC       {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038,
CC       ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394,
CC       ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052,
CC       ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678,
CC       ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354,
CC       ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452,
CC       ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599,
CC       ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869,
CC       ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866,
CC       ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314,
CC       ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587,
CC       ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409,
CC       ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980,
CC       ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute
CC       lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL).
CC       TPLL is characterized by a high white blood cell count, with a
CC       predominance of prolymphocytes, marked splenomegaly, lymphadenopathy,
CC       skin lesions and serous effusion. The clinical course is highly
CC       aggressive, with poor response to chemotherapy and short survival time.
CC       TPLL occurs both in adults as a sporadic disease and in younger AT
CC       patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731,
CC       ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043,
CC       ECO:0000269|PubMed:9573030}.
CC   -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin
CC       lymphomas (BNHL), including mantle cell lymphoma (MCL).
CC       {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620,
CC       ECO:0000269|PubMed:9288106}.
CC   -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic
CC       lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in
CC       the elderly. It is characterized by the accumulation of mature CD5+ B-
CC       lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure.
CC       {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742,
CC       ECO:0000269|PubMed:9892178}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ATMID123.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/atm/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry;
CC       URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U33841; AAC50289.1; -; mRNA.
DR   EMBL; U55757; AAB38309.1; -; Genomic_DNA.
DR   EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55757; AAB38310.1; -; Genomic_DNA.
DR   EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U82828; AAB65827.1; -; Genomic_DNA.
DR   EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X91196; CAA62603.1; -; mRNA.
DR   EMBL; U67092; AAC51298.1; -; Genomic_DNA.
DR   EMBL; AY220758; AAO26044.1; -; Genomic_DNA.
DR   EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA.
DR   EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS31669.1; -.
DR   PIR; A43100; A43100.
DR   RefSeq; NP_000042.3; NM_000051.3.
DR   RefSeq; XP_005271618.2; XM_005271561.4.
DR   RefSeq; XP_005271619.2; XM_005271562.4.
DR   RefSeq; XP_006718906.1; XM_006718843.3.
DR   RefSeq; XP_006718908.1; XM_006718845.1.
DR   RefSeq; XP_011541142.1; XM_011542840.2.
DR   RefSeq; XP_016873278.1; XM_017017789.1.
DR   RefSeq; XP_016873279.1; XM_017017790.1.
DR   PDB; 5NP0; EM; 5.70 A; A/B=1-3056.
DR   PDB; 5NP1; EM; 5.70 A; A=1-3056.
DR   PDB; 6HKA; NMR; -; A=3024-3056.
DR   PDB; 6K9K; EM; 7.82 A; A=1-3056.
DR   PDB; 6K9L; EM; 4.27 A; A/B=1-3056.
DR   PDB; 7NI4; EM; 3.00 A; A/B=1-3056.
DR   PDB; 7NI5; EM; 2.78 A; A/B=1-3056.
DR   PDB; 7NI6; EM; 2.80 A; A/B=1-3056.
DR   PDB; 7SIC; EM; 2.51 A; A/B=1-3056.
DR   PDB; 7SID; EM; 2.53 A; A/C=1-3056.
DR   PDBsum; 5NP0; -.
DR   PDBsum; 5NP1; -.
DR   PDBsum; 6HKA; -.
DR   PDBsum; 6K9K; -.
DR   PDBsum; 6K9L; -.
DR   PDBsum; 7NI4; -.
DR   PDBsum; 7NI5; -.
DR   PDBsum; 7NI6; -.
DR   PDBsum; 7SIC; -.
DR   PDBsum; 7SID; -.
DR   SMR; Q13315; -.
DR   BioGRID; 106962; 286.
DR   CORUM; Q13315; -.
DR   DIP; DIP-182N; -.
DR   IntAct; Q13315; 100.
DR   MINT; Q13315; -.
DR   STRING; 9606.ENSP00000278616; -.
DR   BindingDB; Q13315; -.
DR   ChEMBL; CHEMBL3797; -.
DR   DrugBank; DB00201; Caffeine.
DR   GuidetoPHARMACOLOGY; 1934; -.
DR   GlyGen; Q13315; 4 sites, 2 O-linked glycans (4 sites).
DR   iPTMnet; Q13315; -.
DR   PhosphoSitePlus; Q13315; -.
DR   BioMuta; ATM; -.
DR   DMDM; 317373479; -.
DR   CPTAC; CPTAC-3210; -.
DR   CPTAC; CPTAC-3211; -.
DR   CPTAC; CPTAC-3212; -.
DR   CPTAC; CPTAC-3213; -.
DR   CPTAC; CPTAC-912; -.
DR   CPTAC; CPTAC-913; -.
DR   EPD; Q13315; -.
DR   jPOST; Q13315; -.
DR   MassIVE; Q13315; -.
DR   MaxQB; Q13315; -.
DR   PaxDb; Q13315; -.
DR   PeptideAtlas; Q13315; -.
DR   PRIDE; Q13315; -.
DR   ProteomicsDB; 59303; -.
DR   Antibodypedia; 3596; 1465 antibodies from 47 providers.
DR   CPTC; Q13315; 4 antibodies.
DR   DNASU; 472; -.
DR   Ensembl; ENST00000278616.9; ENSP00000278616.4; ENSG00000149311.20.
DR   Ensembl; ENST00000452508.6; ENSP00000388058.2; ENSG00000149311.20.
DR   Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.20.
DR   GeneID; 472; -.
DR   KEGG; hsa:472; -.
DR   MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3.
DR   UCSC; uc001pkb.1; human.
DR   CTD; 472; -.
DR   DisGeNET; 472; -.
DR   GeneCards; ATM; -.
DR   GeneReviews; ATM; -.
DR   HGNC; HGNC:795; ATM.
DR   HPA; ENSG00000149311; Low tissue specificity.
DR   MalaCards; ATM; -.
DR   MIM; 208900; phenotype.
DR   MIM; 607585; gene.
DR   neXtProt; NX_Q13315; -.
DR   OpenTargets; ENSG00000149311; -.
DR   Orphanet; 100; Ataxia-telangiectasia.
DR   Orphanet; 370109; Ataxia-telangiectasia variant.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 52416; Mantle cell lymphoma.
DR   PharmGKB; PA61; -.
DR   VEuPathDB; HostDB:ENSG00000149311; -.
DR   eggNOG; KOG0892; Eukaryota.
DR   GeneTree; ENSGT00670000098061; -.
DR   HOGENOM; CLU_000178_3_1_1; -.
DR   InParanoid; Q13315; -.
DR   OMA; YSKWAVL; -.
DR   OrthoDB; 80538at2759; -.
DR   PhylomeDB; Q13315; -.
DR   TreeFam; TF101182; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q13315; -.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks.
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-912446; Meiotic recombination.
DR   Reactome; R-HSA-9664873; Pexophagy.
DR   Reactome; R-HSA-9701192; Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function.
DR   Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function.
DR   Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function.
DR   Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51.
DR   Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2.
DR   SignaLink; Q13315; -.
DR   SIGNOR; Q13315; -.
DR   BioGRID-ORCS; 472; 45 hits in 1127 CRISPR screens.
DR   ChiTaRS; ATM; human.
DR   GeneWiki; Ataxia_telangiectasia_mutated; -.
DR   GenomeRNAi; 472; -.
DR   Pharos; Q13315; Tchem.
DR   PRO; PR:Q13315; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q13315; protein.
DR   Bgee; ENSG00000149311; Expressed in calcaneal tendon and 205 other tissues.
DR   ExpressionAtlas; Q13315; baseline and differential.
DR   Genevisible; Q13315; HS.
DR   GO; GO:0005813; C:centrosome; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:1990391; C:DNA repair complex; IDA:MGI.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005819; C:spindle; IEA:Ensembl.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0035173; F:histone kinase activity; IEA:InterPro.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA.
DR   GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL.
DR   GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090398; P:cellular senescence; TAS:Reactome.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006302; P:double-strand break repair; TAS:Reactome.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IEA:Ensembl.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome.
DR   GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IC:BHF-UCL.
DR   GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL.
DR   GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
DR   GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0048599; P:oocyte development; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:1903626; P:positive regulation of DNA catabolic process; IEA:Ensembl.
DR   GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL.
DR   GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL.
DR   GO; GO:1905843; P:regulation of cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:1903978; P:regulation of microglial cell activation; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0000723; P:telomere maintenance; IBA:GO_Central.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl.
DR   CDD; cd05171; PIKKc_ATM; 1.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR015519; ATM/Tel1.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR044107; PIKKc_ATM.
DR   InterPro; IPR021668; TAN.
DR   PANTHER; PTHR11139:SF72; PTHR11139:SF72; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF11640; TAN; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SMART; SM01342; TAN; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage;
KW   DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tumor suppressor.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   CHAIN           2..3056
FT                   /note="Serine-protein kinase ATM"
FT                   /id="PRO_0000088840"
FT   DOMAIN          1940..2566
FT                   /note="FAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534"
FT   DOMAIN          2686..2998
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          3024..3056
FT                   /note="FATC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534,
FT                   ECO:0000255|PROSITE-ProRule:PRU00535"
FT   REGION          1373..1382
FT                   /note="Interaction with ABL1"
FT                   /evidence="ECO:0000269|PubMed:9168117"
FT   REGION          2692..2698
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2867..2875
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2887..2911
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         367
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16858402"
FT   MOD_RES         1893
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16858402"
FT   MOD_RES         1981
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12556884,
FT                   ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402,
FT                   ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854,
FT                   ECO:0007744|PubMed:17525332"
FT   MOD_RES         1983
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         2996
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         3016
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:17923702,
FT                   ECO:0000269|PubMed:30944854"
FT   VARIANT         23
FT                   /note="R -> Q (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs587779858)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041545"
FT   VARIANT         35..3056
FT                   /note="Missing (in AT; dbSNP:rs55861249)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085060"
FT   VARIANT         45
FT                   /note="R -> W (found in a patient with breast cancer;
FT                   unknown pathological significance; dbSNP:rs3218684)"
FT                   /evidence="ECO:0000269|PubMed:11897822"
FT                   /id="VAR_056678"
FT   VARIANT         49
FT                   /note="S -> C (in AT; increases protein abundance;
FT                   dbSNP:rs1800054)"
FT                   /evidence="ECO:0000269|PubMed:10425038,
FT                   ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394,
FT                   ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503,
FT                   ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010798"
FT   VARIANT         68
FT                   /note="I -> V (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083373"
FT   VARIANT         126
FT                   /note="D -> E (in dbSNP:rs2234997)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9711876"
FT                   /id="VAR_010799"
FT   VARIANT         140
FT                   /note="D -> H (in dbSNP:rs55633650)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041546"
FT   VARIANT         182
FT                   /note="V -> L (in dbSNP:rs3218707)"
FT                   /evidence="ECO:0000269|PubMed:10534763"
FT                   /id="VAR_010800"
FT   VARIANT         224
FT                   /note="K -> E (in AT; unknown pathological significance;
FT                   dbSNP:rs145053092)"
FT                   /evidence="ECO:0000269|PubMed:10817650"
FT                   /id="VAR_010801"
FT   VARIANT         250
FT                   /note="R -> Q (in dbSNP:rs56123940)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041547"
FT   VARIANT         292
FT                   /note="P -> L (in AT; associated with lymphoma; decrease
FT                   phosphorylation of target proteins; increases protein
FT                   abundance; dbSNP:rs747727055)"
FT                   /evidence="ECO:0000269|PubMed:10873394,
FT                   ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010802"
FT   VARIANT         323
FT                   /note="I -> V (in AT; loss of protein expression;
FT                   dbSNP:rs587781511)"
FT                   /evidence="ECO:0000269|PubMed:10817650,
FT                   ECO:0000269|PubMed:27664052"
FT                   /id="VAR_010803"
FT   VARIANT         332
FT                   /note="Y -> C (in B-cell chronic lymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9892178"
FT                   /id="VAR_010804"
FT   VARIANT         333
FT                   /note="S -> F (in dbSNP:rs28904919)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041548"
FT   VARIANT         337
FT                   /note="R -> C (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs138398778)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041549"
FT   VARIANT         337
FT                   /note="R -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs202160435)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041550"
FT   VARIANT         341
FT                   /note="V -> I (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083374"
FT   VARIANT         350
FT                   /note="A -> T (in B-cell chronic lymphocytic leukemia;
FT                   dbSNP:rs371713984)"
FT                   /evidence="ECO:0000269|PubMed:10023947"
FT                   /id="VAR_010805"
FT   VARIANT         352
FT                   /note="I -> T (in B-cell chronic lymphocytic leukemia;
FT                   dbSNP:rs369203092)"
FT                   /evidence="ECO:0000269|PubMed:10023947"
FT                   /id="VAR_010806"
FT   VARIANT         374..3056
FT                   /note="Missing (in AT; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_085061"
FT   VARIANT         393..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   dbSNP:rs587776547)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085062"
FT   VARIANT         410
FT                   /note="V -> A (in dbSNP:rs56128736)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041551"
FT   VARIANT         504
FT                   /note="N -> S (in dbSNP:rs56365018)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041552"
FT   VARIANT         514
FT                   /note="G -> D (in dbSNP:rs2235000)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9711876"
FT                   /id="VAR_010807"
FT   VARIANT         540
FT                   /note="C -> Y (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041553"
FT   VARIANT         546
FT                   /note="L -> V (no effect on phosphorylation of target
FT                   proteins; dbSNP:rs2227924)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19431188"
FT                   /id="VAR_041554"
FT   VARIANT         570
FT                   /note="F -> S (in AT; dbSNP:rs777301065)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010808"
FT   VARIANT         582
FT                   /note="F -> L (in dbSNP:rs2235006)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041555"
FT   VARIANT         597
FT                   /note="P -> L (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083375"
FT   VARIANT         661
FT                   /note="D -> A (found in a patient with familial breast
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28202063"
FT                   /id="VAR_083376"
FT   VARIANT         699
FT                   /note="E -> G (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083377"
FT   VARIANT         705..707
FT                   /note="YSS -> FIP (in AT; might be associated with
FT                   susceptibility to cancer)"
FT                   /id="VAR_010809"
FT   VARIANT         707
FT                   /note="S -> P (in dbSNP:rs4986761)"
FT                   /evidence="ECO:0000269|PubMed:10534763,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063"
FT                   /id="VAR_010810"
FT   VARIANT         759
FT                   /note="S -> G (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083378"
FT   VARIANT         761
FT                   /note="T -> S (in dbSNP:rs2235011)"
FT                   /id="VAR_056679"
FT   VARIANT         768
FT                   /note="N -> D (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010812"
FT   VARIANT         785
FT                   /note="R -> C (in AT; dbSNP:rs587778065)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010813"
FT   VARIANT         788
FT                   /note="S -> R (in dbSNP:rs641252)"
FT                   /id="VAR_056680"
FT   VARIANT         813
FT                   /note="N -> S (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083379"
FT   VARIANT         814
FT                   /note="D -> E (in dbSNP:rs3218695)"
FT                   /id="VAR_056681"
FT   VARIANT         848
FT                   /note="E -> Q (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs879254046)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041556"
FT   VARIANT         858
FT                   /note="F -> L (in dbSNP:rs1800056)"
FT                   /evidence="ECO:0000269|PubMed:10534763,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426,
FT                   ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579,
FT                   ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409,
FT                   ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010814"
FT   VARIANT         869
FT                   /note="A -> G (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083380"
FT   VARIANT         872
FT                   /note="P -> S (in dbSNP:rs3218673)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041557"
FT   VARIANT         897
FT                   /note="F -> I (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083381"
FT   VARIANT         924
FT                   /note="R -> W (found in a patient with familial breast
FT                   cancer; unknown pathological significance;
FT                   dbSNP:rs55723361)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:28202063"
FT                   /id="VAR_041558"
FT   VARIANT         935
FT                   /note="T -> A (in dbSNP:rs35813135)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041559"
FT   VARIANT         935
FT                   /note="T -> M (in dbSNP:rs3218708)"
FT                   /id="VAR_056682"
FT   VARIANT         942
FT                   /note="L -> F (in dbSNP:rs3218688)"
FT                   /id="VAR_056683"
FT   VARIANT         950
FT                   /note="L -> R (in AT; dbSNP:rs786203054)"
FT                   /id="VAR_010815"
FT   VARIANT         1001
FT                   /note="L -> Q (in AT; associated with T-cell acute
FT                   lymphoblastic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010816"
FT   VARIANT         1040
FT                   /note="M -> V (found in B-cell non-Hodgkin lymphoma;
FT                   unknown pathological significance; dbSNP:rs3092857)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010817"
FT   VARIANT         1046
FT                   /note="L -> P (in AT; loss of protein expression;
FT                   dbSNP:rs568461905)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077237"
FT   VARIANT         1054
FT                   /note="P -> R (in AT, B-cell chronic lymphocytic leukemia,
FT                   breast cancer patients and familial cancer patients; no
FT                   effect on phosphorylation of target proteins;
FT                   dbSNP:rs1800057)"
FT                   /evidence="ECO:0000269|PubMed:10023947,
FT                   ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503,
FT                   ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869,
FT                   ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010818"
FT   VARIANT         1082
FT                   /note="H -> L (in AT; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_010819"
FT   VARIANT         1091
FT                   /note="E -> D (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9792409"
FT                   /id="VAR_010820"
FT   VARIANT         1171..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   increases protein abundance)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085063"
FT   VARIANT         1179
FT                   /note="S -> F (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041560"
FT   VARIANT         1255
FT                   /note="L -> V (found in a patient with early-onset breast
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:18384426"
FT                   /id="VAR_083382"
FT   VARIANT         1313
FT                   /note="E -> Q (in dbSNP:rs3092841)"
FT                   /id="VAR_056684"
FT   VARIANT         1321
FT                   /note="M -> I (in dbSNP:rs35184530)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041561"
FT   VARIANT         1322
FT                   /note="L -> I (no effect on phosphorylation of target
FT                   proteins; dbSNP:rs144535256)"
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT                   /id="VAR_080300"
FT   VARIANT         1380
FT                   /note="H -> Y (in dbSNP:rs3092856)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041562"
FT   VARIANT         1382
FT                   /note="P -> S (in dbSNP:rs55859590)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041563"
FT   VARIANT         1407
FT                   /note="I -> T (in T-prolymphocytic leukemia;
FT                   dbSNP:rs1234250980)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010821"
FT   VARIANT         1420
FT                   /note="L -> F (in dbSNP:rs1800058)"
FT                   /evidence="ECO:0000269|PubMed:10534763,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503,
FT                   ECO:0000269|PubMed:8797579"
FT                   /id="VAR_010822"
FT   VARIANT         1420
FT                   /note="L -> P (in AT)"
FT                   /evidence="ECO:0000269|PubMed:10817650"
FT                   /id="VAR_010823"
FT   VARIANT         1427
FT                   /note="A -> T (in dbSNP:rs2229021)"
FT                   /id="VAR_056685"
FT   VARIANT         1463
FT                   /note="F -> S (found in B-cell non-Hodgkin lymphoma;
FT                   unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010825"
FT   VARIANT         1465
FT                   /note="L -> P (in AT; decreased phosphorylation of target
FT                   proteins; dbSNP:rs730881391)"
FT                   /evidence="ECO:0000269|PubMed:10234507,
FT                   ECO:0000269|PubMed:19431188"
FT                   /id="VAR_010826"
FT   VARIANT         1466..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   dbSNP:rs730881369)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_085064"
FT   VARIANT         1469
FT                   /note="I -> M (in a renal papillary cancer sample; somatic
FT                   mutation; dbSNP:rs775047783)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041564"
FT   VARIANT         1474
FT                   /note="H -> D (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083383"
FT   VARIANT         1475
FT                   /note="Y -> C (in dbSNP:rs34640941)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041565"
FT   VARIANT         1488
FT                   /note="L -> V (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083384"
FT   VARIANT         1541
FT                   /note="L -> F (in dbSNP:rs3092849)"
FT                   /id="VAR_056686"
FT   VARIANT         1566
FT                   /note="P -> R (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9792409"
FT                   /id="VAR_010827"
FT   VARIANT         1570
FT                   /note="V -> A (in dbSNP:rs140856217)"
FT                   /evidence="ECO:0000269|PubMed:10534763"
FT                   /id="VAR_010828"
FT   VARIANT         1650
FT                   /note="N -> S (in dbSNP:rs55870064)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041566"
FT   VARIANT         1682
FT                   /note="D -> H (in T-prolymphocytic leukemia;
FT                   dbSNP:rs121434217)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010829"
FT   VARIANT         1691
FT                   /note="S -> R (in AT, B-cell chronic lymphocytic leukemia
FT                   and familial cancer patients; no effect on phosphorylation
FT                   of target proteins; dbSNP:rs1800059)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579,
FT                   ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178"
FT                   /id="VAR_010830"
FT   VARIANT         1729
FT                   /note="V -> L (in dbSNP:rs3092907)"
FT                   /id="VAR_056687"
FT   VARIANT         1730..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   dbSNP:rs764389018)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_085065"
FT   VARIANT         1739
FT                   /note="N -> T (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041567"
FT   VARIANT         1743
FT                   /note="T -> I (in AT; associated with preleukemic T-cell
FT                   proliferation; decreased phosphorylation of target
FT                   proteins; dbSNP:rs587779844)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010831"
FT   VARIANT         1812..1813
FT                   /note="AF -> V (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9497252"
FT                   /id="VAR_010832"
FT   VARIANT         1839..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   reduces protein abundance)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085066"
FT   VARIANT         1853
FT                   /note="D -> N (in dbSNP:rs1801516)"
FT                   /evidence="ECO:0000269|PubMed:10397742,
FT                   ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426,
FT                   ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010833"
FT   VARIANT         1853
FT                   /note="D -> V (might contribute to B-cell chronic
FT                   lymphocytic leukemia; dbSNP:rs1801673)"
FT                   /evidence="ECO:0000269|PubMed:10397742,
FT                   ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980,
FT                   ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010834"
FT   VARIANT         1910
FT                   /note="L -> H (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010835"
FT   VARIANT         1913
FT                   /note="V -> G (in AT; dbSNP:rs1060501688)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010836"
FT   VARIANT         1916
FT                   /note="M -> I (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041568"
FT   VARIANT         1945
FT                   /note="A -> T (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041569"
FT   VARIANT         1953
FT                   /note="T -> R (in B-cell chronic lymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:10397742"
FT                   /id="VAR_010837"
FT   VARIANT         1961
FT                   /note="Y -> C (found in a patient with familial pancreatic
FT                   cancer; also found in a lung adenocarcinoma sample; unknown
FT                   pathological significance; decreased phosphorylation of
FT                   target proteins; dbSNP:rs56399311)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808"
FT                   /id="VAR_041570"
FT   VARIANT         1983
FT                   /note="S -> N (in dbSNP:rs659243)"
FT                   /evidence="ECO:0000269|PubMed:16554811"
FT                   /id="VAR_041571"
FT   VARIANT         1991
FT                   /note="E -> D (in a renal clear cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs587782274)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041572"
FT   VARIANT         2016
FT                   /note="D -> G (in AT; unknown pathological significance;
FT                   dbSNP:rs587781302)"
FT                   /evidence="ECO:0000269|PubMed:10425038,
FT                   ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010838"
FT   VARIANT         2023
FT                   /note="G -> R (in AT; loss of protein expression;
FT                   dbSNP:rs11212587)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077238"
FT   VARIANT         2034
FT                   /note="R -> Q (in dbSNP:rs3218670)"
FT                   /id="VAR_056688"
FT   VARIANT         2063
FT                   /note="G -> E (in AT; unknown pathological significance;
FT                   reduces protein abundance; dbSNP:rs866290641)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_010839"
FT   VARIANT         2067
FT                   /note="A -> D (in AT; dbSNP:rs397514577)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010840"
FT   VARIANT         2068
FT                   /note="L -> S (in AT; decreased protein abundance; loss of
FT                   DNA damage induced protein autophosphorylation;
FT                   dbSNP:rs1555114558)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077239"
FT   VARIANT         2079
FT                   /note="V -> I (in dbSNP:rs1800060)"
FT                   /evidence="ECO:0000269|PubMed:8665503"
FT                   /id="VAR_010841"
FT   VARIANT         2080
FT                   /note="Y -> D (in AT; loss of DNA damage induced protein
FT                   autophosphorylation; dbSNP:rs1064795467)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077240"
FT   VARIANT         2105
FT                   /note="R -> T (found in a patient with early-onset breast
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:18384426"
FT                   /id="VAR_083385"
FT   VARIANT         2139
FT                   /note="E -> G (in T-prolymphocytic leukemia; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:9488043"
FT                   /id="VAR_010842"
FT   VARIANT         2164
FT                   /note="E -> K (in T-prolymphocytic leukemia;
FT                   dbSNP:rs1317619286)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010843"
FT   VARIANT         2218
FT                   /note="S -> C (in AT)"
FT                   /evidence="ECO:0000269|PubMed:10817650"
FT                   /id="VAR_010844"
FT   VARIANT         2224..2227
FT                   /note="MALR -> IS (in AT; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_010845"
FT   VARIANT         2227
FT                   /note="R -> C (in AT; unknown pathological significance;
FT                   reduces protein abundance; dbSNP:rs564652222)"
FT                   /evidence="ECO:0000269|PubMed:10873394,
FT                   ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010846"
FT   VARIANT         2246..2252
FT                   /note="CIKDILT -> H (in AT; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:10425038,
FT                   ECO:0000269|PubMed:10873394"
FT                   /id="VAR_010847"
FT   VARIANT         2274
FT                   /note="A -> T (in B-cell chronic lymphocytic leukemia;
FT                   unknown pathological significance; no effect on
FT                   phosphorylation of target proteins; dbSNP:rs567060474)"
FT                   /evidence="ECO:0000269|PubMed:10023947,
FT                   ECO:0000269|PubMed:19431188"
FT                   /id="VAR_010848"
FT   VARIANT         2287
FT                   /note="G -> A (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance;
FT                   dbSNP:rs1800061)"
FT                   /evidence="ECO:0000269|PubMed:28726808,
FT                   ECO:0000269|PubMed:8665503"
FT                   /id="VAR_010849"
FT   VARIANT         2307
FT                   /note="L -> F (found in patients with familial pancreatic
FT                   cancer; also found in a lung adenocarcinoma sample; unknown
FT                   pathological significance; dbSNP:rs56009889)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:28726808"
FT                   /id="VAR_041573"
FT   VARIANT         2332
FT                   /note="L -> P (in dbSNP:rs4988111)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041574"
FT   VARIANT         2335
FT                   /note="T -> K (in dbSNP:rs3092831)"
FT                   /id="VAR_056689"
FT   VARIANT         2356
FT                   /note="I -> F (in a renal clear cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs876658517)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041575"
FT   VARIANT         2396
FT                   /note="T -> S (in T-prolymphocytic leukemia; also found in
FT                   a patient with early-onset breast cancer; unknown
FT                   pathological significance; dbSNP:rs370559102)"
FT                   /evidence="ECO:0000269|PubMed:18384426,
FT                   ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010850"
FT   VARIANT         2408
FT                   /note="S -> L (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs730881315)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041576"
FT   VARIANT         2418
FT                   /note="K -> KK (in mantle cell lymphoma)"
FT                   /evidence="ECO:0000269|PubMed:10397742,
FT                   ECO:0000269|PubMed:10706620"
FT                   /id="VAR_010851"
FT   VARIANT         2420
FT                   /note="A -> P (in B-cell chronic lymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:10397742"
FT                   /id="VAR_010852"
FT   VARIANT         2423
FT                   /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)"
FT                   /evidence="ECO:0000269|PubMed:10397742,
FT                   ECO:0000269|PubMed:10706620"
FT                   /id="VAR_010853"
FT   VARIANT         2424
FT                   /note="V -> G (in AT; also found in B-cell chronic
FT                   lymphocytic leukemia and T-prolymphocytic leukemia; may be
FT                   associated with increased risk for breast cancer; decreased
FT                   phosphorylation of target proteins; dbSNP:rs28904921)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106,
FT                   ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178"
FT                   /id="VAR_010854"
FT   VARIANT         2427..2428
FT                   /note="Missing (in AT; also found in T-prolymphocytic
FT                   leukemia; lack of phosphorylation of target proteins)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835,
FT                   ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010855"
FT   VARIANT         2438
FT                   /note="T -> I (in dbSNP:rs147604227)"
FT                   /evidence="ECO:0000269|PubMed:10817650,
FT                   ECO:0000269|PubMed:8808599"
FT                   /id="VAR_010856"
FT   VARIANT         2442
FT                   /note="Q -> P (in T-prolymphocytic leukemia; also in a lung
FT                   adenocarcinoma sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010857"
FT   VARIANT         2443
FT                   /note="R -> Q (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs587782310)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041577"
FT   VARIANT         2464
FT                   /note="C -> R (found in patients with familial pancreatic
FT                   cancer; also found in a small cell lung cancer sample;
FT                   unknown pathological significance; dbSNP:rs55801750)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:28726808"
FT                   /id="VAR_041578"
FT   VARIANT         2470
FT                   /note="Y -> D (in AT; dbSNP:rs876659365)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010858"
FT   VARIANT         2486
FT                   /note="R -> G (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9573030"
FT                   /id="VAR_010859"
FT   VARIANT         2491
FT                   /note="W -> R (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9792410"
FT                   /id="VAR_010860"
FT   VARIANT         2492
FT                   /note="L -> R (in dbSNP:rs56399857)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041579"
FT   VARIANT         2524
FT                   /note="A -> P (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083386"
FT   VARIANT         2531
FT                   /note="M -> T (found in patients with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083387"
FT   VARIANT         2546..2548
FT                   /note="Missing (in AT; also found in T-prolymphocytic
FT                   leukemia and T-cell acute lymphoblastic leukemia; lack of
FT                   phosphorylation of target proteins)"
FT                   /evidence="ECO:0000269|PubMed:10817650,
FT                   ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600,
FT                   ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452,
FT                   ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599,
FT                   ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358,
FT                   ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010861"
FT   VARIANT         2547..2549
FT                   /note="Missing (in AT; dbSNP:rs587776547)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085067"
FT   VARIANT         2554
FT                   /note="H -> D (in AT; lack of phosphorylation of target
FT                   proteins)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010862"
FT   VARIANT         2570
FT                   /note="E -> G (in dbSNP:rs28904920)"
FT                   /id="VAR_056690"
FT   VARIANT         2625..2626
FT                   /note="DA -> EP (in AT; dbSNP:rs267606668)"
FT                   /id="VAR_010864"
FT   VARIANT         2625
FT                   /note="D -> E (in AT; unknown pathological significance;
FT                   dbSNP:rs1196903858)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085068"
FT   VARIANT         2625
FT                   /note="D -> Q (in AT; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:10817650"
FT                   /id="VAR_010863"
FT   VARIANT         2626
FT                   /note="A -> P (in AT; unknown pathological significance;
FT                   dbSNP:rs267606669)"
FT                   /evidence="ECO:0000269|PubMed:10873394"
FT                   /id="VAR_085069"
FT   VARIANT         2627
FT                   /note="Y -> H (in AT; loss of protein expression)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077241"
FT   VARIANT         2640
FT                   /note="T -> I (in dbSNP:rs4988125)"
FT                   /id="VAR_056691"
FT   VARIANT         2656
FT                   /note="L -> P (in AT; dbSNP:rs121434218)"
FT                   /evidence="ECO:0000269|PubMed:9450874"
FT                   /id="VAR_010865"
FT   VARIANT         2662
FT                   /note="Missing (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010866"
FT   VARIANT         2664
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   dbSNP:rs1471563800)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_085070"
FT   VARIANT         2666
FT                   /note="T -> A (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs745775382)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041580"
FT   VARIANT         2668
FT                   /note="E -> G (in AT; unknown pathological significance; no
FT                   effect on phosphorylation of target proteins)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010868"
FT   VARIANT         2695
FT                   /note="G -> A (in T-prolymphocytic leukemia and B-cell
FT                   chronic lymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:10023947,
FT                   ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010869"
FT   VARIANT         2702
FT                   /note="I -> R (in AT; dbSNP:rs876659735)"
FT                   /id="VAR_010870"
FT   VARIANT         2709
FT                   /note="G -> S (in dbSNP:rs3218680)"
FT                   /id="VAR_056692"
FT   VARIANT         2719
FT                   /note="R -> H (found in a patient with early-onset breast
FT                   cancer; unknown pathological significance;
FT                   dbSNP:rs55982963)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18384426"
FT                   /id="VAR_041581"
FT   VARIANT         2722
FT                   /note="L -> R (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010871"
FT   VARIANT         2725
FT                   /note="D -> G (found in T-prolymphocytic leukemia; unknown
FT                   pathological significance; dbSNP:rs1555128314)"
FT                   /evidence="ECO:0000269|PubMed:9334731"
FT                   /id="VAR_010872"
FT   VARIANT         2725
FT                   /note="D -> V (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010873"
FT   VARIANT         2726
FT                   /note="A -> V (in AT; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_010874"
FT   VARIANT         2732
FT                   /note="F -> L (in T-prolymphocytic leukemia;
FT                   dbSNP:rs876659619)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010875"
FT   VARIANT         2765
FT                   /note="G -> S (may contribute to breast cancer; lack of
FT                   phosphorylation of target proteins; dbSNP:rs748634900)"
FT                   /evidence="ECO:0000269|PubMed:10534763,
FT                   ECO:0000269|PubMed:19431188"
FT                   /id="VAR_010876"
FT   VARIANT         2810
FT                   /note="K -> Q (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083388"
FT   VARIANT         2810
FT                   /note="Missing (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010877"
FT   VARIANT         2824
FT                   /note="C -> Y (in AT; dbSNP:rs876660927)"
FT                   /evidence="ECO:0000269|PubMed:9150358"
FT                   /id="VAR_010878"
FT   VARIANT         2827
FT                   /note="F -> C (in AT; mild; decreased phosphorylation of
FT                   target proteins; dbSNP:rs121434216)"
FT                   /evidence="ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314"
FT                   /id="VAR_010879"
FT   VARIANT         2829
FT                   /note="P -> L (in AT; dbSNP:rs938431501)"
FT                   /evidence="ECO:0000269|PubMed:9711876"
FT                   /id="VAR_010880"
FT   VARIANT         2832
FT                   /note="R -> C (in AT; also found in B-cell non-Hodgkin
FT                   lymphoma; increases protein abundance; dbSNP:rs587779872)"
FT                   /evidence="ECO:0000269|PubMed:10817650,
FT                   ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106,
FT                   ECO:0000269|PubMed:9443866"
FT                   /id="VAR_010881"
FT   VARIANT         2832
FT                   /note="R -> H (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083389"
FT   VARIANT         2834
FT                   /note="F -> L (in AT; decreased protein abundance)"
FT                   /evidence="ECO:0000269|PubMed:27664052"
FT                   /id="VAR_077242"
FT   VARIANT         2842
FT                   /note="P -> R (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs879254065)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041582"
FT   VARIANT         2849..3056
FT                   /note="Missing (in AT; unknown pathological significance;
FT                   dbSNP:rs587778080)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_085071"
FT   VARIANT         2849
FT                   /note="R -> P (in AT; dbSNP:rs587782202)"
FT                   /evidence="ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010882"
FT   VARIANT         2855..2856
FT                   /note="SV -> RI (in AT; lack of phosphorylation of target
FT                   proteins; dbSNP:rs587781353)"
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT                   /id="VAR_010884"
FT   VARIANT         2855
FT                   /note="S -> R (in AT; unknown pathological significance;
FT                   dbSNP:rs780905851)"
FT                   /evidence="ECO:0000269|PubMed:10425038"
FT                   /id="VAR_010883"
FT   VARIANT         2860
FT                   /note="Missing (in AT)"
FT                   /evidence="ECO:0000269|PubMed:7792600,
FT                   ECO:0000269|PubMed:8845835"
FT                   /id="VAR_010885"
FT   VARIANT         2867
FT                   /note="G -> R (in AT)"
FT                   /evidence="ECO:0000269|PubMed:8698354,
FT                   ECO:0000269|PubMed:9887333"
FT                   /id="VAR_010886"
FT   VARIANT         2870
FT                   /note="D -> N (in dbSNP:rs55798854)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041583"
FT   VARIANT         2871..2872
FT                   /note="RH -> S (in T-prolymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:9288106"
FT                   /id="VAR_010887"
FT   VARIANT         2890
FT                   /note="L -> V (in T-prolymphocytic leukemia;
FT                   dbSNP:rs587779874)"
FT                   /evidence="ECO:0000269|PubMed:9288106,
FT                   ECO:0000269|PubMed:9488043"
FT                   /id="VAR_010888"
FT   VARIANT         2904
FT                   /note="E -> G (in AT; dbSNP:rs786202826)"
FT                   /evidence="ECO:0000269|PubMed:8845835"
FT                   /id="VAR_010889"
FT   VARIANT         2909
FT                   /note="R -> G (in AT)"
FT                   /evidence="ECO:0000269|PubMed:9792410"
FT                   /id="VAR_010890"
FT   VARIANT         2974
FT                   /note="P -> L (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083390"
FT   VARIANT         3003
FT                   /note="N -> D (in AT; decreased protein abundance;
FT                   dbSNP:rs1137889)"
FT                   /evidence="ECO:0000269|PubMed:27664052,
FT                   ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678,
FT                   ECO:0000269|PubMed:8665503"
FT                   /id="VAR_077243"
FT   VARIANT         3006
FT                   /note="A -> P (found in T-prolymphocytic leukemia; unknown
FT                   pathological significance; dbSNP:rs876658767)"
FT                   /evidence="ECO:0000269|PubMed:9334731"
FT                   /id="VAR_010892"
FT   VARIANT         3008
FT                   /note="R -> C (in AT; also found in T-prolymphocytic
FT                   leukemia and mantle cell lymphoma; lack of phosphorylation
FT                   of target proteins; dbSNP:rs587782292)"
FT                   /evidence="ECO:0000269|PubMed:10706620,
FT                   ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188,
FT                   ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043,
FT                   ECO:0000269|PubMed:9872980"
FT                   /id="VAR_010893"
FT   VARIANT         3008
FT                   /note="R -> H (in B-cell chronic lymphocytic leukemia;
FT                   dbSNP:rs587781894)"
FT                   /evidence="ECO:0000269|PubMed:10397742"
FT                   /id="VAR_010894"
FT   VARIANT         3018
FT                   /note="K -> N (in B-cell chronic lymphocytic leukemia)"
FT                   /evidence="ECO:0000269|PubMed:10397742"
FT                   /id="VAR_010895"
FT   VARIANT         3029
FT                   /note="G -> D (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083391"
FT   VARIANT         3056
FT                   /note="V -> L (found in a patient with familial pancreatic
FT                   cancer; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:28726808"
FT                   /id="VAR_083392"
FT   MUTAGEN         367
FT                   /note="S->A: Loss of IR-induced S-367 autophosphorylation.
FT                   Reduced correction of cell cycle checkpoint defects and
FT                   DNA-repair activity. No effect on S-1893 nor S-1981
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:16858402"
FT   MUTAGEN         1807
FT                   /note="K->E: Decreased phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         1893
FT                   /note="S->A: Loss of IR-induced S-1893 autophosphorylation.
FT                   Reduced correction of cell cycle checkpoint defects and
FT                   DNA-repair activity. No effect on S-367 nor S-1981
FT                   autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:16858402"
FT   MUTAGEN         1941
FT                   /note="V->L: Decreased phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         1981
FT                   /note="S->A: Loss of IR-induced S-1981 autophosphorylation.
FT                   Reduced correction of cell cycle checkpoint defects and
FT                   DNA-repair activity. No effect on S-367 nor S-1893
FT                   autophosphorylation. No dimer disruption."
FT                   /evidence="ECO:0000269|PubMed:12556884,
FT                   ECO:0000269|PubMed:16858402"
FT   MUTAGEN         1981
FT                   /note="S->D,E: Disrupts the dimer."
FT                   /evidence="ECO:0000269|PubMed:12556884,
FT                   ECO:0000269|PubMed:16858402"
FT   MUTAGEN         2019
FT                   /note="Y->C: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2039
FT                   /note="E->K: Decreased phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2338
FT                   /note="L->P: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2394
FT                   /note="S->L: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2452
FT                   /note="L->P: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2685
FT                   /note="S->T: No effect on phosphorylation of target
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2699
FT                   /note="P->L: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2708
FT                   /note="D->N: Decreased phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2730
FT                   /note="Q->P: Loss of phosphorylation of target proteins."
FT                   /evidence="ECO:0000269|PubMed:19431188"
FT   MUTAGEN         2870
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9733515"
FT   MUTAGEN         2875
FT                   /note="N->K: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9733515"
FT   MUTAGEN         3016
FT                   /note="K->Q: Mimics acetylation, preventing
FT                   dephosphorylation and subsequent ATM deactivation during
FT                   the late stage of DNA damage response."
FT                   /evidence="ECO:0000269|PubMed:30944854"
FT   MUTAGEN         3016
FT                   /note="K->R: Loss of DNA damage-inducible acetylation.
FT                   Retains constitutive kinase activity, but blocks DNA
FT                   damage-induced kinase activation. Disrupts dimer and
FT                   abolishes S-1981 autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17923702"
FT   MUTAGEN         3018
FT                   /note="K->R: Retains DNA damage-inducible acetylation and
FT                   S-1981 autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17923702"
FT   CONFLICT        46
FT                   /note="H -> N (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        56
FT                   /note="N -> I (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        313
FT                   /note="Y -> N (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        488
FT                   /note="W -> G (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        554
FT                   /note="T -> A (in Ref. 1; AAC50289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        750
FT                   /note="K -> N (in Ref. 1; AAC50289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        754
FT                   /note="Q -> K (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        887
FT                   /note="E -> G (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1003
FT                   /note="Q -> L (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1049
FT                   /note="L -> W (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1089
FT                   /note="A -> V (in Ref. 7; CAA62603)"
FT                   /evidence="ECO:0000305"
FT   HELIX           6..17
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           20..33
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           36..41
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           57..73
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           90..108
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          109..112
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           117..129
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          130..133
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           135..148
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            149..151
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           153..158
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           161..176
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           183..201
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           207..209
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           210..222
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          223..225
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           229..242
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          244..246
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           248..268
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           273..290
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           292..294
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           298..300
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           306..323
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          324..326
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           343..356
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           393..402
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            407..409
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           410..422
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           424..426
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           429..431
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   HELIX           432..442
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          445..447
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           452..466
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           474..492
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            493..496
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           498..500
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   HELIX           501..513
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           521..524
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            525..527
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           528..530
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           536..548
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           572..580
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           597..600
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            605..607
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           608..615
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          617..619
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           620..628
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            634..636
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           646..655
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           684..704
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            707..709
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           713..731
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           737..741
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           744..765
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           771..786
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          792..794
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           795..806
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           809..822
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           887..889
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           892..911
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           920..930
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            933..935
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           941..953
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          957..959
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           963..970
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           973..979
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            980..982
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           984..994
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           995..997
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           998..1002
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1009..1030
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1031..1033
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           1036..1052
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1060..1063
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1066..1069
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1070..1076
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1077..1079
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1083..1092
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1093..1096
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1113..1132
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1136..1138
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           1144..1164
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1169..1181
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1187..1201
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1206..1212
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1214..1223
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1227..1229
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   TURN            1231..1233
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   HELIX           1236..1238
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1244..1261
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1265..1275
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1279..1285
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1287..1294
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1295..1297
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1306..1322
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1325..1327
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1328..1330
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1332..1338
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1340..1348
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1383..1396
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1397..1399
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1404..1408
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1413..1428
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1432..1450
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1453..1455
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   TURN            1456..1460
FT                   /evidence="ECO:0007829|PDB:7NI5"
FT   HELIX           1461..1477
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1485..1508
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1512..1514
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1517..1524
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1525..1528
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1532..1545
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1546..1549
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1553..1560
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1569..1571
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   HELIX           1572..1582
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1583..1585
FT                   /evidence="ECO:0007829|PDB:7NI6"
FT   HELIX           1590..1601
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1607..1610
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1611..1623
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1625..1634
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1639..1641
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1643..1658
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1664..1677
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1694..1702
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1706..1721
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1727..1742
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1744..1753
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1754..1756
FT                   /evidence="ECO:0007829|PDB:7NI4"
FT   HELIX           1759..1763
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1764..1767
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            1785..1789
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1792..1795
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1802..1815
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1822..1825
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1828..1831
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1835..1851
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1857..1875
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1903..1917
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          1922..1924
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1927..1930
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1938..1947
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1951..1973
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           1986..1996
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2001..2012
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2016..2019
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2023..2028
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2029..2038
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2042..2051
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2057..2070
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2074..2087
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2093..2105
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2124..2136
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2140..2159
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2166..2168
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2170..2190
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2195..2211
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2212..2214
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2217..2236
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2244..2264
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2269..2281
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2290..2301
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2305..2322
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2328..2348
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2353..2359
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2361..2370
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2377..2405
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2408..2421
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2437..2475
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2481..2483
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2484..2492
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2493..2496
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2498..2506
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2508..2510
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2513..2519
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2520..2524
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2529..2531
FT                   /evidence="ECO:0007829|PDB:7SID"
FT   STRAND          2533..2535
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2537..2551
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2553..2564
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2565..2567
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2568..2572
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2593..2612
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2614..2632
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2637..2640
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2652..2655
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2659..2663
FT                   /evidence="ECO:0007829|PDB:7NI6"
FT   STRAND          2673..2675
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2682..2686
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2688..2692
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2695..2697
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2700..2706
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2707..2709
FT                   /evidence="ECO:0007829|PDB:7NI4"
FT   STRAND          2711..2720
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2723..2740
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2743..2747
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2757..2759
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2761..2768
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2773..2775
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2776..2781
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2783..2785
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2787..2791
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2798..2807
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2808..2810
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2813..2825
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2833..2838
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2842..2866
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2873..2875
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2876..2879
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2880..2882
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2885..2887
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2896..2899
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2900..2902
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          2906..2908
FT                   /evidence="ECO:0007829|PDB:7NI4"
FT   HELIX           2912..2916
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   TURN            2922..2925
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2926..2940
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2942..2953
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           2964..2970
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           3002..3018
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   STRAND          3020..3025
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           3028..3040
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           3042..3046
FT                   /evidence="ECO:0007829|PDB:7SIC"
FT   HELIX           3050..3052
FT                   /evidence="ECO:0007829|PDB:7SIC"
SQ   SEQUENCE   3056 AA;  350687 MW;  C0B4866E1E3199E2 CRC64;
     MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV
     FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL
     LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ
     DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL
     KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK
     GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED
     TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI
     SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL
     LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC
     CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH
     SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM
     DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR
     LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM
     QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED
     DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM
     LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP
     LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT
     VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD
     NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN
     PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET
     FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV
     IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD
     MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH
     FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK
     IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ
     VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK
     LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ
     LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP
     IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI
     LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE
     NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN
     LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK
     RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG
     SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA
     MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY
     QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK
     RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ
     EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ
     YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV
     CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR
     IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK
     RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM
     YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR
     SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT
     QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK
     IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL
     SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF
     MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE
     QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN
     SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ
     SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV
//
